Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GCP-001 (gGlu-HMRG) is an activatable fluorescent probe developed by GORYO Chemical for the intraoperative detection of cancer, specifically breast cancer. The probe is based on the hydroxymethyl rhodamine green (HMRG) fluorophore, which is initially in a non-fluorescent state due to quenching by a gamma-glutamyl group. Upon contact with the enzyme gamma-glutamyltransferase (GGT), which is frequently overexpressed on the surface of cancer cells, the gamma-glutamyl group is enzymatically cleaved, rapidly generating a strong fluorescent signal. This mechanism allows for real-time, high-contrast visualization of tumor margins and micro-metastases during surgery, aiding in complete resection. The agent has been evaluated in Phase 1 clinical trials at Kyushu University Beppu Hospital and is being developed in partnership with Solasia Pharma.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gGlu-HMRG.